Featured News

2026

Expand

Collapse

JAN 2026

InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease ZURICH, Switzerland –…

Read

2025

Expand

Collapse

OCT 2025

InterAx Biotech AG appoints Andrew Roberts as Chief Executive Officer. Seasoned drug development and portfolio strategy leader to fully leverage…

Read

2024

Expand

Collapse

FEB 2024

InterAx Biotech unveils breakthroughs by identifying novel cellular modes of action unlocking the rational design of superior drugs for multiple…

Read

2023

Expand

Collapse

NOV 2023

InterAx Biotech announces being the recipient of a highly competitive European grant to fund drug development and reports financing highlights.…

Read

OCT 2023

InterAx Biotech announces the appointment of seasoned pharmaceutical executive, Mark Levick, MD, Ph.D. as new Board Director. Zürich, Switzerland –…

Read

MAY 2023

InterAx Biotech to Apply its Leading AI and Cell Signalling Technology to Support Target Validation for a Sosei Heptares GPCR…

Read

2022

Expand

Collapse

JUL 2022

InterAx Biotech, MS Center Amsterdam and the Vrije Universiteit Amsterdam join forces to unlock a novel target to promote remyelination…

Read

2021

Expand

Collapse

SEP 2021

Early and successful completion of European Union’s H2020 Project    September 2021, Switzerland   Today, InterAx Biotech AG, a Biotech…

Read

APR 2021

InterAx Biotech further strengthens its Scientific Advisory Board – welcoming Prof. Dr. Ruedi Aebersold as a member   April 2021,…

Read

2020

Expand

Collapse

APR 2020

A Spanish-Swiss Liaison to fight COVID-19

Read

APR 2020

InterAx Biotech supporting the COVID-19 initiative SARS-CoV-2/ACE-2 pseudovirus entry blocking assay

Read

2019

Expand

Collapse

DEC 2019

InterAx Biotech and GPCR Therapeutics Inc collaborate for the identification of compounds with superior biological properties targeting GPCR heteromers

Read

SEPT 2019

European Union awards InterAx with Horizon 2020 SME Instrument Phase 2 for the integration of machine learning into the InterAx…

Read

AUG 2019

InterAx Biotech and Boehringer Ingelheim collaborate for enabling the in-depth characterization of drug candidates using the proprietary InterAx systems biology…

Read

MAY 2019

Next EU Training Network ONCORNET2.0 on oncogenic GPCR networks   The EU has granted 4M euro to Martine Smit and…

Read

APR 2019

InterAx Biotech and Lundbeck A/S entered an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx…

Read

FEB 2019

InterAx Biotech received the Seal of Excellence by the European Commission   February 2019, Switzerland-Belgium : InterAx is proud to…

Read

JAN 2019

InterAx Biotech closed a financing round of CHF 3 million   January 2019, Switzerland : InterAx, a Biotech company pioneering…

Read

2018

Expand

Collapse

SEP 2018

InterAx listed for the second year in a raw as TOP 100 Swiss Startup!   September 2018, Switzerland : A…

Read

JUL 2018

European Union awards InterAx with Horizon 2020 SME Instrument Phase I July 2018, Switzerland-Belgium: InterAx Biotech AG today announces the…

Read

JUL 2018

See what Einstein, InterAx and the Nobel Prize have in common

Read

MAY 2018

InterAx Biotech and Vrije Universiteit Amsterdam enter a collaboration to unlock novel chemical space for chemokine therapeutics   Villigen –…

Read

APR 2018

New immune oncology drug molecules expected to result from leadXpro / InterAx partnership   Villigen, Switzerland, April 18 2018leadXpro AG…

Read

2017

Expand

Collapse

DEC 2017

InterAx achieves milestone that triggers second part of seed investment ahead of schedule   December 2017, Switzerland-Boston: InterAx announced today…

Read

SEP 2017

InterAx listed in the TOP100 Swiss Startup 2017   September 2017, Switzerland: 100 investors and experts selected InterAx as one…

Read

AUG 2017

InterAx and Prof. Peter Kolb from the Philipps-University Marburg initiated a collaboration for lead discovery   Villigen, Switzerland, 22nd of…

Read

AUG 2017

InterAx welcomes Prof. Dr. Michel Bouvier as new Advisory Board Member   August 2017, Switzerland-Canada   Scientific advisory boards set…

Read

JUL 2017

InterAx is nominated for the TOP 100 Swiss Startup Award 2017!   July 2017, Switzerland : We are nominated for…

Read

FEB 2017

We welcome our new CSO Maria Waldhoer!   February 2017, Switzerland : Dr. Maria Waldhoer recently joined our team as…

Read

2016

Expand

Collapse

DEC 2016

Seed financing round closed, undisclosed amount   December 2016, Switzerland / U.S. : InterAx Biotech AG has closed a seed…

Read

NOV 2016

InterAx wins the Swiss UpStart Challenge in the category Technology, receives 20,000 CHF   November 2016, Switzerland: The Swiss UpStart…

Read

OCT 2016

InterAx Finalist of the Swiss Technology Award October 2016, Basel Switzerland: Each year, outstanding technology-based innovations and developments from start-ups,…

Read

JUN 2016

6th place at >>venture>> Business Plan competition for InterAx!   June 2016, Zürich, Switzerland: InterAx made it with a 6th…

Read

NOV 2016

Dr. Martin Ostermaier and InterAx awarded Venture Leaders in Life Sciences Boston 2016 prize   April 2016, Switzerland: InterAx CEO…

Read

FEB 2016

InterAx wins Venture Kick Final, CHF 130K Investment   February 2016, Switzerland: A jury of entrepreneurs, investors, and scientists has…

Read

2015

Expand

Collapse

JUN 2015

InterAx gets the Stage II Kick, wins 20,000 CHF   June 2015, Lausanne, Switzerland:  InterAx was selected by the Venture…

Read

FEB 2015

  InterAx wins 10,000 CHF in pre-seed capital   February 2015, Lausanne, Switzerland:  InterAx was two of four companies selected…

Read

2014

Expand

Collapse

DEC 2014

Dr. Martin Ostermaier named Pioneer Fellow, InterAx Biotech awarded 150,000 CHF in equity free capital   December 2014, Zürich, Switzerland:…

Read